Toggle navigation
Home
Search
Services
Blog
Contact
About
Phase I Single and Multiple-Dose Safety and Pharmacokinetic Clinical S-261985081
University of Illinois at Chi
Search grants from University of Illinois at Chi
Share this grant:
:
:
Abstract
Funding
Institution
Related projects
Comments
Recent in Grantomics:
Your institution
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
LA Basin CSU MHIRT Program
Role of the E3L gene in poxvirus pathogenesis
Core-- Monoclonal Antibody
Transthyretin Mutants From Serum Using Immunoprecipitation
High-Resolution Structural Studies of Insect Viruses
Recently added grants:
Targeting TET1 signaling to treat acute myeloid leukemia
Targeting the Unfolded Protein Response in PanNETs
Understanding the full spectrum of epigenetic vulnerability in cancer through the delineation of DNA methylation function in gene 3' end
Augmenting Pancreatic Cancer Immunotherapy via TGF? Pathway Inhibition
Investigating the Molecular Basis of Olaparib Resistance in BRCA2-Deficient Prostate Cancer
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
Division of Cancer Prevention And Control (NCI)
Type
Research and Development Contracts (N01)
Project #
N01CN985081-003
Application #
7191436
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
2005
Total Cost
Indirect Cost
Institution
Name
University of Illinois at Chi
Department
Type
DUNS #
City
State
Country
Zip Code
Related projects
NIH 2006
N01 CN
Phase I Single and Multiple-Dose Safety and Pharmacokinetic Clinical S-261985081
/ University of Illinois at Chi
NIH 2005
N01 CN
Phase I Single and Multiple-Dose Safety and Pharmacokinetic Clinical S-261985081
/ University of Illinois at Chi
NIH 2004
N01 CN
Phase I Single and Multiple-Dose Safety and Pharmacokinetic Clinical S-261985081
/ University of Illinois at Chi
Comments
Be the first to comment on this grant